Search

… Tuesday, July 1, 2014 Physician-scientist Ingo Mellinghoff has been designated the incumbent of the Evnin Family Chair in Neuro-Oncology. Established through the generosity of Dr. Tony Evnin, a general partner of venture capital firm Venrock and a member of Memorial Sloan Kettering’s Boards of Overseers

Across the United States, there is a disparity in the rate of people who are candidates for a partial nephrectomy — those with small renal tumors — and those who actually have the procedure.

… Wednesday, April 18, 2018 Across the United States, there is a disparity in the rate of people who are candidates for a partial nephrectomy — those with small renal tumors — and those who actually have the procedure. Research shows that this is mainly because the operation is challenging and associated

Researchers identify a biomarker that could predict which lung cancer patients will respond to chemotherapy.

… Tuesday, October 26, 2021 Lung adenocarcinoma, the most common form of  lung cancer  in the United States, can be difficult to cure unless diagnosed at an early stage. Surgery is effective at removing early-stage tumors, but more than half of patients with stage 2 or 3 disease have a recurrence of their

New MSK research uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare providers about the benefits and risks of commercial genetic testing.

… Tuesday, September 3, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare

… Tuesday, July 1, 2014 Neurosurgeon Mark Bilsky , received the Willet F. Whitmore Award for Clinical Excellence at the 2014 Academic Convocation ceremony and Commencement for students from the Louis V. Gerstner Graduate School of Biomedical Sciences. The annual award is presented to a clinician whose

Human papillomavirus (HPV)–associated oropharyngeal cancer is on the rise, but at Memorial Sloan Kettering Cancer Center, we have updated our standard of care to substantially reduce the radiation dose to elective regions.

… Tuesday, December 10, 2019 Human papillomavirus (HPV)–associated oropharyngeal cancer is on the rise, but at Memorial Sloan Kettering Cancer Center, we have updated our standard of care to substantially reduce the radiation dose to elective regions. In our paper, published recently in the journal Practical

Meet the four young ambassadors featured in the annual Stop & Shop campaign to fundraise for the Department of Pediatrics at Memorial Sloan Kettering.

… Monday, June 11, 2018 Summary For nearly 20 years, Memorial Sloan Kettering has partnered with Stop & Shop supermarkets to raise funds for pediatric cancer research. Meet the four spunky kids representing MSK across New York, New Jersey, and Connecticut for this year’s campaign. The next time you visit

A phase 3 trial for myelofibrosis found that adding pelabresib to ruxolitinib was more effective than ruxolitinib alone and did not significantly increase side effects.

… Tuesday, April 29, 2025 An international phase 3 clinical trial of a new drug combination for treating the blood cancer  myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

… Thursday, February 27, 2014 New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain. Published in the February 27 issue of Cell , the study found that tumor cells that reach the brain — and successfully

A blood condition related to aging can lead to misinterpreting tumor data.

… Tuesday, June 5, 2018 Summary MSK researchers have found that clonal hematopoiesis (CH) can be misinterpreted as tumor mutations in sequencing tests. CH is a blood condition related to aging that can cause mutations in the blood. Misreading such results could affect treatment decisions. MSK-IMPACT TM